Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Stopped early · Phase 1/Phase 2
Conditions studied: Acute Lymphoblastic Leukemia
In brief
The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute lymphoblastic leukemia (ALL). This is a dose escalation study in which after 2 induction cycles participants may be put on maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.
Key facts
- Study ID
- NCT02404220
- Run by
- Gilead Sciences
- People needed
- 30
- Starts
- 2015-05-06
- Expected to finish
- 2018-12-17
- Last updated by the study team
- 2020-01-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- UCLA — Los Angeles, California, United States
- UC Irvine Medical Center — Orange, California, United States
- University of California San Diego (UCSD) — San Diego, California, United States
- University of Chicago — Chicago, Illinois, United States
- Hackensack University Medical Center — Hackensack, New Jersey, United States
- Memorial Sloan-Kettering — New York, New York, United States
- The Ohio State University — Columbus, Ohio, United States
- Bon Secour St. Francis Hospital — Greenville, South Carolina, United States
- University of WA — Seattle, Washington, United States
- Princess Margaret — Toronto, Ontario, Canada
- Medizinische Klinik mit Schwerpunkt Hepatologie & Gastroenterology — Berlin, Germany
- Medizinische Klinik und Poliklinik I — Würzburg, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.